Cargando…
Drug therapy for double-hit lymphoma
Double-hit lymphoma (DHL) is a rare type of aggressive B-cell lymphoma defined as a high-grade B-cell lymphoma (HGBCL) with the presence of MYC, BCL2 and/or BCL6 rearrangements. Patients usually present with rapidly progressive and advanced stage of disease and, commonly, with extranodal involvement...
Autores principales: | Phuoc, Vania, Sandoval-Sus, Jose, Chavez, Julio C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905641/ https://www.ncbi.nlm.nih.gov/pubmed/31844420 http://dx.doi.org/10.7573/dic.2019-8-1 |
Ejemplares similares
-
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
por: Sandoval-Sus, Jose, et al.
Publicado: (2021) -
Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions
por: Chavez, Julio C, et al.
Publicado: (2021) -
Altered pathways and targeted therapy in double hit lymphoma
por: Zhuang, Yuxin, et al.
Publicado: (2022) -
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
por: Jain, Michael D, et al.
Publicado: (2018) -
Advancing the management of double hit lymphoma
por: Landsburg, Daniel J.
Publicado: (2017)